<DOC>
	<DOC>NCT01478529</DOC>
	<brief_summary>A study to evaluate how much of the active compound of mirabegron comes into the blood circulation when given as a controlled-release pill as compared to given intravenously.</brief_summary>
	<brief_title>A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation</brief_title>
	<detailed_description>All participants will receive both oral and iv formulations, separated by a washout period. Treatment arm A will receive a lower dose of mirabegron; Treatment arm B will receive a higher dose of mirabegron.</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Body weight between 60.0 and 100.0 kg and Body Mass Index between 18.0 and 30.0 kg/m2 Known or suspected hypersensitivity to βadrenergic receptor agonists or constituents of the formulations used Clinically significant elevation of serum creatinine or liver enzymes as evidenced by creatinine &gt;150 ųmol/L; ASAT, ALAT or LDH&gt; 2x ULN; ɣGT &gt; 3x ULN and/or abnormal serum bilirubin Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug Subjects taking β blockers or β agonists (eye drops allowed) Any clinically significant history of upper gastrointestinal symptoms (such as nausea, vomiting, abdominal discomfort or upset, or heartburn) in the 4 weeks prior to the first admission to the Research Unit Any clinically significant history of any other disease or disorder gastrointestinal, cardiovascular, respiratory, ophthalmologic, renal, hepatic, neurological, dermatological, psychiatric or metabolic Any clinically significant abnormality following the investigator's review of the prestudy physical examination, ECG and clinical laboratory tests QTcB interval of &gt; 430 (mean QTcB of two measurements &gt; 430msec) Abnormal pulse rate measurement (&lt;40 or &gt;90 bpm) at the prestudy visit after subject has been resting in supine position for 5 min. Abnormal blood pressure measurements taken at the prestudy visit after subject has been resting in supine position for 5 min as follows: Systolic blood pressure &lt;95 or &gt;160 mmHg Diastolic blood pressure &lt;40 or &gt;90 mmHg Positive orthostatic test at screening i.e. any symptoms of dizziness, lightheadedness etc. and a fall of &gt; 20 mmHg in systolic blood pressure after 2 min standing and an increase in pulse rate of ≥ 20 bpm Regular use of any prescribed or OTC drugs except paracetamol up to 3 g/day, in the 4 weeks prior to admission to the Research Unit OR any use of such drugs in the 2 weeks prior to first admission to the Research Unit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Phase 1</keyword>
</DOC>